BCEL

Atreca Stock Price

18.53
-0.61 (-3.19%)
Upgrade to Real-Time
Regular Market
18.53
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Atreca Inc BCEL NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.61 -3.19% 18.53 18.32 19.46 18.99 19.14 13:39:28
Bid Price Ask Price Spread Spread % News
18.47 18.60 0.13 0.7% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,551 75,207 $ 18.71 $ 1,407,224 215,392 9.51 - 29.35
Last Trade Time Type Quantity Stock Price Currency
13:39:34 1 $ 18.47 USD

Atreca Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 522.60M 28.20M 14.29M $ - $ - -4.98 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -69.80k 3.10%

more financials information »

Atreca News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BCEL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week22.8723.1718.3220.34128,326-4.34-18.98%
1 Month19.7526.3017.9120.95213,705-1.22-6.18%
3 Months14.7226.3013.200618.85178,5333.8125.88%
6 Months14.6029.3510.880718.17207,2883.9326.92%
1 Year16.6029.359.5116.66161,4161.9311.63%
3 Years19.9029.359.5116.73162,201-1.37-6.88%
5 Years19.9029.359.5116.73162,201-1.37-6.88%

Atreca Description

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.


Your Recent History
NASDAQ
BCEL
Atreca
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.